Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 21, 2025Discover OncologyOpen Access

METTL3 and METTL14 drive pancreatic adenocarcinoma progression via m6A-dependent alternative splicing in PANC-1 cells

View Full Paper
Ask AI
Bookmark
Share

Authors

BTBo TangLWL WangDWDong Wei

Discussion

Loading...

Member takes

Overview

Analysis of METTL3 and METTL14 reveals their role in regulating alternative splicing in pancreatic cancer, indicating potential therapeutic targets.

Key Points

  • Altered gene expression significantly impacts pathways linked to pancreatic cancer progression and survival.
  • Key findings highlighted that 17 genes were both differentially expressed and m6A-modified, revealing critical targets in the disease.
  • Observational analysis focused on METTL3 and METTL14's role in gene regulation through m6A-dependent splicing mechanisms.
  • These findings highlight the importance of METTL3 and METTL14 as potential biomarkers and targets for pancreatic cancer treatment.

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/68af409acf1dd9ea359ec976https://doi.org/10.1007/s12672-025-03393-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The methyltransferase METTL3 promotes the progression of breast cancer cells via regulating EGF m6A modification2025
  2. 2METTL3-mediated activation of Sonic Hedgehog signaling promotes breast cancer progression2025
  3. 3Targeting METTL3 disrupts oncogenic transcriptional programs and activates immune and apoptotic pathways in Acute Myeloid Leukemia2025
  4. 4METTL13 Promotes Pre-Leukemic Transformation and the Development of Pediatric Leukemia2025
  5. 5Recent advances in small molecules targeting the METTL32025